← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Targeted Therapy Technologies, Llc
Somerset, NJ
$7,740,381
Total funding
5
Grants
Funding over time
peak $2.8M · FY2010–24$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
DOD$3,660,917 · 2
NIH$2,769,464 · 1
FDA$1,310,000 · 2
By mechanism
—$3,660,917 · 2
RC3$2,769,464 · 1
R01$1,310,000 · 2
Investigators at Targeted Therapy Technologies, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Episcleral Chemotherapy as Salvage Therapy for Eyes with Retinoblastoma$2,769,464
RC3 · FY2010 · CA
EPISCLERAL THARAPY FOR IED-RELATED OPHTHALMIC INJURY$2,661,000
· FY2011 · Department of Defense
EPISCLERAL COX-2 AND STEROID AGENTS AS COMPREHENSIVE THERAPEUTIC INTERVENTIONS$999,917
· FY2015 · Department of Defense
Retinoblastoma Phase II Expanded Access Clinical Trial$650,000
R01 · FY2024 · FD
Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma$220,000
R01 · FY2022 · FD
Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma$220,000
R01 · FY2019 · FD
Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma$220,000
R01 · FY2021 · FD